XML 67 R55.htm IDEA: XBRL DOCUMENT
v3.25.2

Commitments and Contingencies - License Agreements (Details) - Related party |  |  | 1 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | ---
Sep. 07, 2021 USD ($) shares | Nov. 01, 2019 USD ($) shares | Mar. 31, 2023 | Jun. 30, 2025 | Mar. 27, 2023 item
TheraCour Pharma Inc |  |  |  |  |
Commitments and Contingencies |  |  |  |  |
Percentage of net sales allocated for royalty payments (in percent) |  | 15.00% |  | 15.00% |
Issuance of shares | shares |  | 75,000 |  |  |
Cash upon completion of Phase I Clinical Trials |  | $ 1,500,000 |  |  |
Cash upon completion of Phase II Clinical Trials |  | 2,500,000 |  |  |
Cash upon completion of Phase III Clinical Trials |  | $ 5,000,000 |  |  |
KMPL |  |  |  |  |
Commitments and Contingencies |  |  |  |  |
Number of clinical test drug candidates granted for the use, sale, or offer of sale in India | item |  |  |  |  | 2
Percentage of clinical trials fees |  |  | 30.00% |  |
Percentage of royalty fee |  |  | 70.00% |  |
Series A Preferred Stock |  |  |  |  |
Commitments and Contingencies |  |  |  |  |
Shares value upon initiation of Phase III Clinical Trials | $ 100,000 |  |  |  |
Series A Preferred Stock | TheraCour Pharma Inc |  |  |  |  |
Commitments and Contingencies |  |  |  |  |
Percentage of net sales allocated for royalty payments (in percent) | 15.00% |  |  |  |
Issuance of shares | shares | 50,000 |  |  |  |
Cash upon completion of Phase I Clinical Trials | $ 2,000,000 |  |  |  |
Cash upon completion of Phase II Clinical Trials | 2,500,000 |  |  |  |
Cash upon completion of Phase III Clinical Trials | $ 5,000,000 |  |  |  |
Number of shares issuable upon execution of agreement | shares | 100,000 |  |  |  |
Threshold Period for Issuance of Shares Upon Execution of Agreement | 30 days |  |  |  |
Stock Issued During Period Value New Issues Initiation Of Phase1 Clinical Trials | $ 1,500,000 |  |  |  |
Shares value upon completion of Phase III Clinical Trials | $ 500,000 |  |  |  |

X
- Definition The line item information about commitment and contingencies. + References No definition available. + Details
Name: | nnvc_CommitmentsAndContingenciesLineItems
Namespace Prefix: | nnvc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of clinical test drug candidates granted for the use, sale, or offer of sale in India. + References No definition available. + Details
Name: | nnvc_NumberOfClinicalTestDrugCandidatesGrantedForUseSaleOrOfferOfSaleInIndia
Namespace Prefix: | nnvc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The number of shares issuable upon execution of agreement. + References No definition available. + Details
Name: | nnvc_NumberOfSharesIssuableUponExecutionOfAgreement
Namespace Prefix: | nnvc_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of clinical trials manager fee. + References No definition available. + Details
Name: | nnvc_PercentageOfClinicalTrialsFees
Namespace Prefix: | nnvc_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty expense calculated as a percentage of net sales. + References No definition available. + Details
Name: | nnvc_PercentageOfNetSalesAllocatedForRoyaltyPayments
Namespace Prefix: | nnvc_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of royalty fee paid. + References No definition available. + Details
Name: | nnvc_PercentageOfRoyaltyFee
Namespace Prefix: | nnvc_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition It represents the amount of stock issued during period, value, new issues, cash upon completion of phase I clinical trials. + References No definition available. + Details
Name: | nnvc_StockIssuedDuringPeriodValueNewIssuesCashUponCompletionOfPhase1ClinicalTrials
Namespace Prefix: | nnvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition It represents the amount of stock issued during period, value, new issues, cash upon completion of phase II clinical trials. + References No definition available. + Details
Name: | nnvc_StockIssuedDuringPeriodValueNewIssuesCashUponCompletionOfPhase2ClinicalTrials
Namespace Prefix: | nnvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition It represents the amount of stock issued during period, value, new issues, cash upon completion of phase III clinical trials. + References No definition available. + Details
Name: | nnvc_StockIssuedDuringPeriodValueNewIssuesCashUponCompletionOfPhase3ClinicalTrials
Namespace Prefix: | nnvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition It represents the amount of stock issued during period, value, new issues, upon completion of phase III clinical trials. + References No definition available. + Details
Name: | nnvc_StockIssuedDuringPeriodValueNewIssuesCompletionOfPhase3ClinicalTrials
Namespace Prefix: | nnvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition It represents the amount of stock issued during period, value, new issues, upon initiation of phase I clinical trials. + References No definition available. + Details
Name: | nnvc_StockIssuedDuringPeriodValueNewIssuesInitiationOfPhase1ClinicalTrials
Namespace Prefix: | nnvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition It represents the amount of stock issued during period, value, new issues, upon initiation of phase III clinical trials. + References No definition available. + Details
Name: | nnvc_StockIssuedDuringPeriodValueNewIssuesInitiationOfPhase3ClinicalTrials
Namespace Prefix: | nnvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The threshold period for issuance of shares upon execution of agreement. + References No definition available. + Details
Name: | nnvc_ThresholdPeriodForIssuanceOfSharesUponExecutionOfAgreement
Namespace Prefix: | nnvc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=nnvc_TheracourPharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=nnvc_KarveerMeditechPvt.LtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |